Evaluation of the immune system response to Diphtheria and Tetanus vaccination in HIV positive patients

Seroepidemiology of Diphtheria and Tetanus antibodies and response to the booster dose of Td in HIV infected patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211204076N8

Enrollment

300

Registered

2012-12-25

Start date

2013-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV AIDS. Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases

Interventions

According to basic level of Diphtheria and Tetanus serum antibody, if the Ab level is under the baseline for protection of our patients, we will vaccinate them and then at 1 and 6 month after vaccinat

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age above 18 and under 65 years; accepting the consent form and unresponsive to previous vaccination Exclusion criteria: pregnancy; age under 18 and above 65 years and positive antibody for Diphteria and Tetanus.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
DT Antibody. Timepoint: Before vaccination, 1 and 6 month after vaccination. Method of measurement: Serum antibody level.	—

Secondary

Measure	Time frame
CD4 count. Timepoint: Before vaccination. Method of measurement: flowcytometery.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMinoo Mohraz MD

Iranian research Center for HIV AIDS (IRCHA)

ircha@tums.ac.ir+98 21 6694 7984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026